BRIEF-FDA grants Pharming Group RUCONEST 12-year reference exclusivity

Thu Oct 8, 2015 1:16am EDT
 
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

Oct 8 (Reuters) - Pharming Group NV :

* Announces that the U.S. Food and Drug Administration (FDA) has granted 12 years of exclusivity to RUCONEST (C1 esterase inhibitor ) 50 IU/kg Source text for Eikon: Further company coverage: (Gdynia Newsroom)